BigHat Biosciences
An AI and synthetic-biology platform that designs and engineers antibody therapeutics.
$75MSeries C
ParticipantAV
Alexandria Venture Investments
Activity from announced rounds
All recorded activity
- Rounds participated in
- 11
- Confirmed lead rounds
- 0 10 roles undisclosed
- New companies
- 11 First participation on record · 0 follow-on
- Funding in participating rounds
- $710M 11 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
11 in all activityLeal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedKhartis Therapeutics
Develops oral small molecule therapies for immunological and chronic diseases
$50MSeries B
Role not disclosedVedana Therapeutics
Develops next-generation therapies for migraine prevention
$46MSeries A
Role not disclosedSonoThera
Develops ultrasound-mediated nonviral genetic medicines
$125MSeries B
Role not disclosedCREATE Medicines
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
$122MSeries B
Role not disclosedFathom Therapeutics
Uses quantum chemistry and AI to design novel drug molecules
$47MSeries A
Role not disclosedAlloy Therapeutics
Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners.
$40MSeries E
Role not disclosedTen63 Therapeutics
Develops AI-driven drug discovery platform for first- and best-in-class therapeutics
$45MStrategic
Role not disclosedTRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedProxima
Develops AI-driven drug discovery for proximity therapeutics
$80MUndisclosed
Role not disclosed